GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (FRA:VSC) » Definitions » Net Income Including Noncontrolling Interests

4SC AG (FRA:VSC) Net Income Including Noncontrolling Interests : €-8.24 Mil (TTM As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is 4SC AG Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

4SC AG's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was €-3.57 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.24 Mil.

4SC AG Net Income Including Noncontrolling Interests Historical Data

The historical data trend for 4SC AG's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG Net Income Including Noncontrolling Interests Chart

4SC AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.96 -18.99 -9.63 -14.36 -8.24

4SC AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.50 -11.34 -3.02 -4.66 -3.57

4SC AG Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-8.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4SC AG Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of 4SC AG's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

4SC AG (FRA:VSC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (FRA:VSC) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XTER:MDG1 XTER:HPHA XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX ALNY OCSE:GMAB BGNE BMRN INCY TECH UTHR
Traded in Other Exchanges
VSC:Germany
Address
Fraunhoferstraße 22, Planegg-Martinsried, DEU, 82152
Website
https://www.4sc.com
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG (FRA:VSC) Headlines

No Headlines